Related references
Note: Only part of the references are listed.CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
Kristen Fousek et al.
LEUKEMIA (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
Agrima Mian et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature
Ajay Major et al.
LEUKEMIA & LYMPHOMA (2021)
Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments
Xinjie Xu et al.
FRONTIERS IN IMMUNOLOGY (2021)
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
Nawid Albinger et al.
GENE THERAPY (2021)
CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities
Maryam Akhoundi et al.
CELLULAR ONCOLOGY (2021)
Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma
Shruti Gupta et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment
Yelei Guo et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19
Peter Braendstrup et al.
CYTOTHERAPY (2020)
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
Noelle Frey et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Hanren Dai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature
Jingsheng Hua et al.
ONCOTARGETS AND THERAPY (2020)
Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)
Robert David Sandler et al.
FRONTIERS IN IMMUNOLOGY (2020)
Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults
Surabhi B. Vora et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Psychosocial care for children receiving chimeric antigen receptor (CAR) T-cell therapy
Angela Steineck et al.
PEDIATRIC BLOOD & CANCER (2020)
CAR-T design: Elements and their synergistic function
Jayapriya Jayaraman et al.
EBIOMEDICINE (2020)
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
Runxia Gu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Embryonic stem cell-derived mesenchymal stem cells promote colon epithelial integrity and regeneration by elevating circulating IGF-1 in colitis mice
Jun Xu et al.
THERANOSTICS (2020)
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman et al.
NATURE REVIEWS IMMUNOLOGY (2020)
CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia
Jyoti Naik et al.
HAEMATOLOGICA (2019)
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Kris M. Mahadeo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
Kevin A. Hay et al.
BLOOD (2019)
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells
Philipp Karschnia et al.
BLOOD (2019)
Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
Juanjuan Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Engineering and Design of Chimeric Antigen Receptors
Sonia Guedan et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
Nirav N. Shah et al.
FRONTIERS IN ONCOLOGY (2019)
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
Jing Pan et al.
LEUKEMIA (2019)
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
Susanne Hofmann et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
Sara Ghorashian et al.
NATURE MEDICINE (2019)
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
Kevin J. Curran et al.
BLOOD (2019)
Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses
Colleen Annesley et al.
BLOOD (2019)
Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
Xiao Han et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
Xinjie Xu et al.
FRONTIERS IN IMMUNOLOGY (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile
Sara Ghorashian et al.
BLOOD (2019)
Anti-CD19/CD22 Dual CAR-T Therapy for Refractory and Relapsed B-Cell Acute Lymphoblastic Leukemia
Junfang Yang et al.
BLOOD (2019)
Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions
Lauren C. Fleischer et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL
George Hucks et al.
BLOOD CANCER JOURNAL (2019)
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations
Robert Weinkove et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2019)
Current status and hurdles for CAR-T cell immune therapy
Ruocong Zhao et al.
BLOOD SCIENCE (2019)
Predicting responses to platin chemotherapy agents with biochemically-inspired machine learning
Eliseos J. Mucaki et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers
Vinay Prasad
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts
Ping-Pin Zheng et al.
DRUG DISCOVERY TODAY (2018)
Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
Dok Hyun Yoon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
Jian Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study
Weili Sun et al.
LEUKEMIA (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia
Matthew J. Oberley et al.
PEDIATRIC BLOOD & CANCER (2018)
The development of CAR design for tumor CAR-T cell therapy
Dandan Xu et al.
Oncotarget (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
Zijun Zhao et al.
ACTA PHARMACEUTICA SINICA B (2018)
Chimeric antigen receptor T-cell therapy hits the market
Michael W. Boyer
IMMUNOTHERAPY (2018)
CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum
Asen Bagashev et al.
MOLECULAR AND CELLULAR BIOLOGY (2018)
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Marco Ruella et al.
NATURE MEDICINE (2018)
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
Alexander I. Salter et al.
SCIENCE SIGNALING (2018)
Tumor Antigen Escape from CAR T-cell Therapy
Robbie G. Majzner et al.
CANCER DISCOVERY (2018)
The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
Matthew H. Forsberg et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia
Melanie D. Whittington et al.
JAMA PEDIATRICS (2018)
Engineering CAR-T Cells for Improved Function Against Solid Tumors
Michael A. Morgan et al.
FRONTIERS IN IMMUNOLOGY (2018)
Simultaneous Targeting of CD19 and CD22: Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study
Persis J. Amrolia et al.
BLOOD (2018)
Late Effects of CD19-Targeted CAR-T Cell Therapy
Ana Cordeiro et al.
BLOOD (2018)
Sequential allogeneic and autologous CAR-T-cell therapy to treat an immune-compromised leukemic patient
Jian-Ping Zhang et al.
BLOOD ADVANCES (2018)
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
Zhenguang Wang et al.
BIOMARKER RESEARCH (2018)
Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis
Irbaz Bin Riaz et al.
IMMUNOTHERAPY (2017)
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
Cameron J. Turtle et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
Jun Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke et al.
MOLECULAR THERAPY (2017)
Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase
Alec J. Walker et al.
MOLECULAR THERAPY (2017)
Development of CAR T cells designed to improve antitumor efficacy and safety
Janneke E. Jaspers et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Novel agents for the treatment of childhood leukemia: an update
Ertugrul Eryilmaz et al.
ONCOTARGETS AND THERAPY (2017)
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
T. Terwilliger et al.
BLOOD CANCER JOURNAL (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
Oladapo O. Yeku et al.
SCIENTIFIC REPORTS (2017)
Global Manufacturing of CAR T Cell Therapy
Bruce L. Levine et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2017)
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Kevin A. Hay et al.
BLOOD (2017)
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
Diogo Gomes-Silva et al.
BLOOD (2017)
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Rebecca A. Gardner et al.
BLOOD (2017)
Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia
Hanna A. Knaus et al.
CURRENT DRUG TARGETS (2017)
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
Julie C. Fitzgerald et al.
CRITICAL CARE MEDICINE (2017)
CAR-T Cell Therapy for Lymphoma
Carlos A. Ramos et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
Rebecca Gardner et al.
BLOOD (2016)
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
Xiaojun Liu et al.
CANCER RESEARCH (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Superior Therapeutic Index in Lymphoma Therapy: CD30+ CD34+ Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack
Andreas A. Hombach et al.
MOLECULAR THERAPY (2016)
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
Cameron J. Turtle et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
All-trans retinoic acid and interferon-α increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors
K. Mihara et al.
BLOOD CANCER JOURNAL (2016)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
CAR models: next-generation CAR modifications for enhanced T-cell function
Daniel Abate-Daga et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Toxicity and management in CAR T-cell therapy
Challice L. Bonifant et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL
Shannon L. Maude et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)
Kazusa Ishii et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2016)
Tocilizumab-Refractory Cytokine Release Syndrome (CRS) Triggered By Chimeric Antigen Receptor (CAR)-Transduced T Cells May Have Distinct Cytokine Profiles Compared to Typical CRS
Kazusa Ishii et al.
BLOOD (2016)
Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
Shannon L. Maude et al.
BLOOD (2016)
Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
Victoria Hillerdal et al.
BIODRUGS (2015)
TSLPR: a new CAR in the showroom for B-ALL
David Marc Davies et al.
BLOOD (2015)
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Shannon L. Maude et al.
BLOOD (2015)
Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein
Haiying Qin et al.
BLOOD (2015)
How I treat hemophagocytic lymphohistiocytosis in the adult patient
Alison M. Schram et al.
BLOOD (2015)
Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells
Andrew G. Evans et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia
Elias Jabbour et al.
CANCER (2015)
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
Zeguo Zhao et al.
CANCER CELL (2015)
Adoptive T-cell therapy for cancer: The era of engineered T cells
Chiara Bonini et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic
Connie P. M. Duong et al.
MOLECULAR IMMUNOLOGY (2015)
IL-6 as a keystone cytokine in health and disease
Christopher A. Hunter et al.
NATURE IMMUNOLOGY (2015)
The pharmacology of second-generation chimeric antigen receptors
Sjoukje J. C. van der Stegen et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Acute Lymphoblastic Leukemia in Children
Stephen P. Hunger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells
Elena Catalan et al.
ONCOIMMUNOLOGY (2015)
Target Antigen Density Governs the Efficacy of Anti-CD20-CD28-CD3 ζ Chimeric Antigen Receptor-Modified Effector CD8+ T Cells
Keisuke Watanabe et al.
JOURNAL OF IMMUNOLOGY (2015)
The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
Michael Hudecek et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
The importance of TSLP in allergic disease and its role as a potential therapeutic target
Antonella Cianferoni et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study
Roberta De Angelis et al.
LANCET ONCOLOGY (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Distinct phosphatases antagonize the p53 response in different phases of the cell cycle
Indra A. Shaltiel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Hematopoietic Stem Cell Transplantation-50 Years of Evolution and Future Perspectives
Israel Henig et al.
RAMBAM MAIMONIDES MEDICAL JOURNAL (2014)
Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
Michael Hudecek et al.
CLINICAL CANCER RESEARCH (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Concise Review: Acute Graft-Versus-Host Disease: Immunobiology, Prevention, and Treatment
Anthony D. Sung et al.
STEM CELLS TRANSLATIONAL MEDICINE (2013)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N. Kochenderfer et al.
BLOOD (2012)
Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
Stephen P. Hunger et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
John Scholler et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
How I treat hemophagocytic lymphohistiocytosis
Michael B. Jordan et al.
BLOOD (2011)
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Renier J. Brentjens et al.
BLOOD (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Michael C. Milone et al.
MOLECULAR THERAPY (2009)
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
Carmine Carpenito et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Retargeting of human T cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor
Scott Wilkie et al.
JOURNAL OF IMMUNOLOGY (2008)
Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane
Scott T. James et al.
JOURNAL OF IMMUNOLOGY (2008)
Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study
Vinod Pullarkat et al.
BLOOD (2008)
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial
Anthony V. Moorman et al.
BLOOD (2007)
HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
Jan-Inge Henter et al.
PEDIATRIC BLOOD & CANCER (2007)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
The role of extracellular spacer regions in the optimal design of chimeric immune receptors - Evaluation of four different scFvs and antigens
RD Guest et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain
HM Finney et al.
JOURNAL OF IMMUNOLOGY (2004)
Share Paper
